These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 32283060

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro.
    Li XN, Bu HM, Ma XH, Lu S, Zhao S, Cui YL, Sun J.
    Exp Clin Endocrinol Diabetes; 2017 Feb; 125(2):91-97. PubMed ID: 28008585
    [Abstract] [Full Text] [Related]

  • 3. Bisdemethoxycurcumin Augments Docetaxel Efficacy for Treatment of Prostate Cancer.
    Song Y, Ruan J, Liu S, Yu H.
    Biol Pharm Bull; 2024 Feb; 47(8):1437-1446. PubMed ID: 39143009
    [Abstract] [Full Text] [Related]

  • 4. Diospyros rhodocalyx Kurz induces mitochondrial-mediated apoptosis via BAX, Bcl-2, and caspase-3 pathways in LNCaP human prostate cancer cell line.
    Phongsuwichetsak C, Suksrichavalit T, Chatupheeraphat C, Eiamphungporn W, Yainoy S, Yamkamon V.
    PeerJ; 2024 Feb; 12():e17637. PubMed ID: 38966207
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.
    Shi L, Ji Y, Jiang X, Zhou L, Xu Y, Li Y, Jiang W, Meng P, Liu X.
    Cardiovasc Diabetol; 2015 Feb 07; 14():18. PubMed ID: 25855361
    [Abstract] [Full Text] [Related]

  • 9. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines.
    Karaca B, Degirmenci M, Ozveren A, Atmaca H, Bozkurt E, Karabulut B, Sanli UA, Uslu R.
    Cancer Chemother Pharmacol; 2015 Jun 07; 75(6):1273-80. PubMed ID: 25925002
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.
    Dirican A, Atmaca H, Bozkurt E, Erten C, Karaca B, Uslu R.
    Clin Transl Oncol; 2015 Feb 07; 17(2):145-51. PubMed ID: 25060568
    [Abstract] [Full Text] [Related]

  • 12. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
    Yu L, Wu X, Chen M, Huang H, He Y, Wang H, Li D, Du Z, Zhang K, Goodin S, Zheng X.
    Int J Med Sci; 2017 Feb 07; 14(4):356-366. PubMed ID: 28553168
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS, Hong SK, Oh MM, Yoon CY, Jeong SJ, Byun SS, Cheon J, Lee SE, Moon du G.
    Anticancer Res; 2014 Jul 07; 34(7):3457-68. PubMed ID: 24982354
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.